<DOC>
	<DOCNO>NCT01867190</DOCNO>
	<brief_summary>This study ass safety efficacy intra-arterial infusion intramuscular injection autologous , bone marrow-derived stem cell preparation ( ASCT01 ) versus placebo patient critical limb ischemia exhaust medical surgical therapeutic option . The safety tolerability evaluate regular monitoring general physical condition , vital sign , occurrence AE SAE , respectively . Furthermore , standard biochemical blood variable ( red white blood cell count , Hb , Ht , platelet , sodium , potassium , chloride , calcium , phosphor , ASAT , ALAT , bilirubin , total protein , albumin , AP , cholesterol ( LDL , HDL ) , triglyceride , urea creatinine , immunoglobulin , HBA1c , C-peptide ) check treatment well 30 90 day treatment .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Bone Marrow Derived Stem Cells Patients With Critical Limb Ischemia</brief_title>
	<detailed_description>Efficacy determine number collateral artery assess magnetic resonance angiography baseline 3 month , rate major amputation ( ankle ) affect limb within 3 month unchanged critical limb ischemia affect limb 3 month define less 15 % change tcPO2 ABI absolute ankle pressure.Efficacy endpoint 3 month . Clinical endpoint safety measure 12 month .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>1 . Male Female patient age group 1880yrs . 2 . Established CLI ( confirm Rutherford 4 5 ) angiographic evidence significant infrainguinal arterial occlusive disease 3 . Ankle Brachial Pressure Index ( ABI ) ≤ 0.6 absolute ankle blood pressure &lt; 60 mm Hg TcPO2 &lt; 20 mmHg without tissue loss TcPO2 &lt; 40 mmHg tissue loss alternatively toe Brachial Pressure Index ( TBI ) less 0.5 absolute toe blood pressure le 50 mm Hg 4 . No surgical interventional option revascularization response best standard care deliver confirm vascular surgeon and/or physician . 5 . No immediate lifethreatening complication CLI would demand immediate amputation . 6 . Patients able understand requirement study , willing provide voluntary write informed consent , abide study requirement , agree return require followup visit . 7 . On optimal medical therapy 8 . If diabetic , HgbA1c &lt; 10 % 1 . Acute life threaten complication limb ischemia need immediate limb amputation avoid death clinical deterioration 2 . Patients confirm Rutherford 6 condition extensive tissue damage 3 . Patients document terminal illness cancer concomitant disease process life expectancy le 6 month . 4 . Patients history severe alcohol drug abuse within 3 month screen . 5 . Known bone marrow diseases preclude transplantation . 6 . Endstage renal failure regular dialysis treatment . Creatinine ≥2.0 mg/dl 7 . Patients already enrol another investigational drug trial complete within 1month . 8 . Pregnancy . 9 . Patients test positive HIV screen1or2 , Hepatitis C antibody Hepatitis B surfaceantigen , HepatitisBcore Antibody , Syphilis screen 10 . Myocardial infarction / CVA / TIA within past three month prior enrollment 11 . Revascularization procedure target limb within 6 week prior enrollment 12 . Laboratory value show below* 13 . Currently take immunosuppressive agent 14 . If diabetic , diagnosis proliferative retinopathy 15 . Patients infected ulcer systemic infection *Laboratory Values : Hemoglobin &lt; 10 g/dL Platelet count &lt; 100,000/microL ALT &gt; 60 U/L AST &gt; 60 U/L Bilirubin &gt; 1.0 mg/dL INR &gt; 1.3 unless Coumadin Investigator discretion APTT &gt; 40 second unless Lovenox Heparin Investigator 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>CLI</keyword>
</DOC>